Speakers

Prof. Dr. Karim Nayernia

CEO, International Center for Personalized
Medicine, Germany

Title: Personalized Cell Therapy of cardiovascular diseases

Specialist, Institute of cardiomyopathies,University
Hospital Heidelberg, Germany

Title: Towards Individualized Therapy of Ischemic and Non-Ischemic Heart Failure Patients

Director, Institute for Neurophysiology,
University of Cologne,Germany

Title: Personalized Medicine Based on Induced Pluripotent Stem Cells

Director, German Heart Centre,
Munich,Germany

Title: Multiplicative Effects of CAD Risk Alleles

CEO, European Prevention Center,
Germany

Title: What Is The Privative Potential or Genetic Analysis in Clinical Cardiology?

Head of Centre for Diabetes Research,
University of Western Australia

Title: Genetic Risk Signatures Identifying People at Higher Risk of Cancer, Heart Attack and Other Diseases

CEO, Medler Ferro Woodhouse & Mills, USA

Title: Protecting Personalized Medicine Innovation in Europe and the US: Challenges and Opportunities

CEO, Jain PharmaBiotech, Switzerland

Title: Integration of Biotechnologies for The Development of Personalized Medicine for Cardiovascular Disorders

Head of Human Cardiovascular Studies (NIA),
Johns Hopkins School of Medicine,USA

Title: Precious Medicine in Ambiguous Diseases Individualizing care in Age-Associated Cardiovascular Conditions

Head of the Department of Medicine at Brigham &
Women’s Hospital, Harvard Medical School, USA

Title: Network Medicine: A Path to Precision Cardiovascular Medicine

Business Development Director, Germany

Title: Personalized Medicine: Market considerations and aspects from a Start-Up perspective

CEO of Tartan LLC, USA

Title: RNA-targeting Cas9 Corrects Molecular and Physiological Features of Myotonic Dystrophy Type I”

Principal Investigator, Institute for Neurophysiology,
university of Cologne,Germany

Title: Loss of Genomic Integrity Induced by Lysosphingolipid Imbalance Drives Ageing in the Heart